Ocular chronic graft-versus-host disease (oGVHD) occurs in 40-60% of patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT) [1] . Severe forms of oGVHD can be devastating since they restrict daily activities and severely deteriorate quality of life. The most common clinical manifestations of oGVHD include dry eye syndrome and conjunctival inflammation. Available therapies include a variety of topical and systemic approaches with respect to the severity of the condition. However, there is a lack of effective treatment for steroid refractory disease as well as a paucity of controlled trials in the management of oGVHD. New strategies include autologous tear drops and scleral lenses with some encouraging results [2, 3] . Despite all available therapies, some cases still progress to severe ocular ulcerations and occasionally result in corneal perforation requiring emergency keratoplasty. Moreover, catastrophic consequences with enucleation of the eye and permanent visual impairment have also been described [4] .
Amniotic membrane (AM) is an avascular fetal membrane collected from placental tissue during elective cesarean sections, from donors screened for transmissible infectious diseases. As it lacks HLA-A, HLA-B and HLA-DR antigens, AM is universally tolerated and can be used without fear of rejection. Amniotic membrane transplantation (AMT) is an established technique in the treatment of non-healing skin wounds and severe burns [5] . In ophthalmology, AMT was first developed for severe ocular manifestations of acute Stevens-Johnson syndrome [6] . Today it is being efficiently used for the treatment of various types of keratitis, neurotrophic keratopathy, non-healing corneal ulcers and corneal perforations [7] . The application of AM is simple and well tolerated among recipients, with no serious complications following the procedure [8] . AM typically dissolves over a period of 1-2 weeks; thus, more than one application may be necessary during the acute phase of the disease. Topical medications can be used concurrently, as medication penetration has not been found to be an issue. Two types of AM-cryopreserved and dehydrated are approved for distribution as tissue allografts and are commercially available.
In our institution, AMT is used for the treatment of severe oGVHD refractory to all available local and systemic therapy. Herein we report clinical course and outcomes of first four consecutive patients who underwent the AMT procedure as salvage therapy for oGVHD.
AM-s were manufactured in the institutional tissue bank according to a standardized protocol with the institutional review board approval. The description of the AMT technique is available in Supplementary Information 1. The characteristics of patients and AMT are depicted in Table 1 . First patient was a 26-year-old male who underwent a related allo-HSCT for lymphoblastic transformation of chronic myeloid leukemia (CML) and received three donor lymphocytes infusions (DLI) due to molecular relapse. Six months later, he developed severe chronic GVHD of the mouth and eye that gradually progressed despite corticosteroid treatment and topical therapy, and finally led to corneal perforation. In this case, AMT was used to successfully seal corneal perforation in order to avoid keratoplasty. The procedure led to a durable clinical improvement continuing for 4 years after treatment without the need for systemic immunosuppression. The second patient was a 25-year-old male, transplanted from an unrelated donor for a CML refractory to tyrosine kinase inhibitors, who received one DLI for mixed chimerism and consequently developed chronic GVHD of the skin, liver, lungs and eyes. oGVHD progressed despite local and triple systemic immunosuppressive treatment. In this case, AMT was applied before severe corneal ulcerations developed and led to full clinical recovery. The third patient was a 32-year-old female who underwent an unrelated myeloablative allo-HSCT for myelofibrosis, complicated with acute liver GVHD and slow immune reconstitution. At day +150, she developed a disabling herpetic keratitis and stomatitis, which led to prolonged hospitalization and slow recovery. At day + 280, her vision deteriorated again, this time with signs of severe oGVHD. Concerns about herpes reactivation resulted in hesitation from increasing her immunosuppression. With this rationale, a decision was made to perform AMT, which again led to the healing of cornea and significant clinical improvement (Fig. 1) . Finally, our fourth patient underwent unrelated allo-HSCT at the age of 22 for high-risk myelodysplastic syndrome complicated with toxic epidermal necrolysis of the skin, mucosa and eyes. In this case, chronic oGVHD developed 8 months later, gradually progressing partly due to patient's non-compliance with treatments. This time AMT was applied on two consecutive occasions causing a similarly impressive effect.
In our study, AMT resulted in fast epithelialization of corneal defects and complete resolution of symptoms in all cases. Patients stayed hospitalized until AM dissolved and were monitored for adverse events. No side-effects and no infections were documented. With a median follow-up of 15 months, all four patients remained clinically stable without recurrence of corneal defects or signs of severe oGVHD.
AM has revolutionized the treatment of a variety of severe ocular surface diseases, as it is efficient, readily available and easy to manipulate and apply [9] . This study reports the first successful use of AMT as salvage therapy in severe oGVHD in patients with relative contraindications for the increase of systemic immunosuppression. The use of AMT has been previously described in three cases of oGVHD [4, 10, 11] but in patients who already had corneal perforations. In two of these cases, AMT showed no effect, leading to the conclusion that AMT can be used to reconstruct the ocular surface only in patients with tiny perforations, which was also the case in our first patient. However, in the remaining three patients in this current series, AMT was used before corneal perforations developed. The study presented here demonstrates AMT to be safe, well tolerated and highly effective. In contrast to treatment algorithms for ocular surface diseases, which include AMT late in the protocol, we believe that early intervention with AM is important in severe oGVHD, before serious complications develop.
Several characteristics contribute to the efficacy of the AMT; first of all, it serves as a physical barrier that protects corneal epithelium as it heals, and it reduces pain caused by friction of the eyelids over the surface. Furthermore, it promotes epithelial growth through cell migration, adhesion, and differentiation, while also inhibiting epithelial cell apoptosis [12, 13] . Finally, AM is rich in cytokines, growth factors, and protease inhibitors, which provide its antiinflammatory and anti-scarring effects [14] . In the current report, in addition to its immediate beneficial action on healing of severe corneal ulcerations and its probable effect on preventing perforation, AMT also prevented recurrence of severe oGVHD, highlighting the potential immunomodulatory properties of AM. This effect is in concordance with preclinical results, which suggest that AM-derived cells have the capacity to strongly suppress immune responses, potentially induce peripheral tolerance, and reverse ongoing inflammatory damage [15] .
In conclusion, AMT could become a very valuable procedure for the treatment of refractory cases of invasive oGVHD. Patients with severe ocular surface damage, who have either a high risk for development of infectious complications, or have an increased risk of recurrence of their primary malignancy (and could therefore be harmed by increasing the level of systemic immunosuppression), are the ones that could benefit the most from AMT.
